Rhlmann, F
Figure 2 GLP-1 and GLP-1 Analogs In patients with T2D, GLP-1 and GLP-1 analogs were shown to improve cardiovascular-risk profiles, by reducing body fat content, blood pressure, circulating lipids, and inflammatory markers (76)
Despite retatrutide not being FDA approved, the TRIUMPH-1 Phase 3 results are exciting, showcasing up to 28.3% average weight loss over 80 weeks
According to a survey of elife users, over half of those who experienced side effects reported that their symptoms were gone within one week
And then of course, if you're considering hormone replacement therapy, we wanna confirm your menopausal status or where you're at
it's about medically supervised weight loss, body sculpting that targets what exercise can't touch, and the kind of comprehensive support that actually helps you keep the results long-term